The latest biotech news

News and Trends 24 May 2023

Major progress as Swedish scientists get brain tumors to self destruct

Researchers at the University of Gothenburg in Sweden, working with French colleagues, have successfully developed a method able to kill the aggressive brain tumor glioblastoma. By blocking certain functions in the cell with a docked molecule, the researchers cause the cancer to die of stress.Cancer cells, especially those that form aggressive tumors, are in one […]

May 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 23 May 2023

FDA approval for Rznomics’ glioblastoma treatment trial

Rznomics Inc., a South Korea based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, has received phase 1/2a IND approval from the U.S. FDA for its glioblastoma multiforme (GBM) treatment. RZ-001 initially obtained IND approval for hepatocellular carcinoma (HCC), but Rznomics also found pre-clinical efficacy in GBM models and submitted the IND for […]

May 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 May 2023

AMR research gets £39m shot from UK government

Research initiatives to develop new treatments to tackle antimicrobial resistance (AMR) – known as the “silent killer” – will receive a cash injection of up to £39 million ($48.5 million) from the U.K. government’s Global AMR Innovation Fund (GAMRIF). However, according to the director of Global Health Policy and Senior Policy Fellow at the Center […]

May 23, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 23 May 2023

Vicore reports new data from idiopathic pulmonary fibrosis study

Vicore Pharma Holding AB (publ), has announced an updated interim analysis of its AIR phase 2a trial with C21 in idiopathic pulmonary fibrosis (IPF). With 51 patients enrolled, the data demonstrates that C21 has the potential to transform the treatment of IPF and restore lung function. The disease is currently considered to be incurable and […]

May 23, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 23 May 2023

HuidaGene Therapeutics creates world’s first ‘G to Y’ DNA base-editor

HuidaGene Therapeutics, a clinical-stage genome-editing company, says the National Science Review has published data from its study of the world’s first DNA base editor converting guanine to cytosine/thymine (pyrimidine), or G-to-Y. The company has filed an international patent application for the glycosylase-based guanine base editor (gGBE) and owns the exclusive global rights to the underlying […]

May 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 May 2023

Ironwood acquires VectivBio in $1B deal

Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, and VectivBio Holding AG, a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of approximately $1 billion, net of VectivBio […]

May 23, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 23 May 2023

Take part in a clinical trial? Sure, just pay me

The majority of people in the U.K. (68%) would consider taking part in a clinical trial, it has been revealed today, while half of Brits would also be willing to take part in an early phase clinical trial. Financial payment is the most popular motivation for taking part in a clinical trial, but discovering new […]

May 23, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 22 May 2023

Cancer implications as new molecule can kill ‘zombie’ cells

Over time, the body’s cells stop working properly and begin to accumulate, which eventually leads to tissues aging. Researchers at the UOC (Universitat Oberta de Catalunya) in Spain, in collaboration with the University of Leicester in the U.K. have discovered a new molecule that is able to destroy these old cells without affecting healthy ones. […]

May 22, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 May 2023

FDA approves first topical gene therapy for dystrophic epidermolysis bullosa wound treatment

The U.S. Food and Drug Administration has approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. The approval of Vyjuvek was granted to […]

May 22, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 May 2023

Kelonia presents ‘compelling evidence’ for transformative multiple myeloma treatment

Kelonia Therapeutics, a biotech company working on in vivo gene delivery, has announced the results of preclinical research demonstrating that its in vivo Gene Placement System (iGPS) technology efficiently delivered CAR molecules specifically to T cells at therapeutic dose levels in both mice and non-human primates (NHPs). Kelonia’s iGPS platform enables CAR T cell therapy […]

May 19, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 May 2023

Swedish company develops first effective treatment for hypothyroidism

Prolevi Bio has developed a technology intended to help the 10 to 20% of people who don’t respond to current treatments for underactive thyroid glands. The company has developed a modified release thyroid hormone tablet formulation, mimicking the natural hormone release cycles. In addition, the treatment will be tailored according to each patient’s needs using […]

May 19, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 19 May 2023

Researchers make cancer weight loss pathway discovery

Nearly half of all cancer patients suffer from excessive weight loss due to the loss of adipose and skeletal muscle tissues, or cachexia. This progressive illness not only reduces quality of life for cancer patients but also poses a serious threat for treatment since it obstructs the use of effective medicines, especially in advanced stages. […]

May 19, 2023 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Major progress as Swedish scientists get brain tumors to self destruct

FDA approval for Rznomics’ glioblastoma treatment trial

AMR research gets £39m shot from UK government

Vicore reports new data from idiopathic pulmonary fibrosis study

HuidaGene Therapeutics creates world’s first ‘G to Y’ DNA base-editor

Ironwood acquires VectivBio in $1B deal

Take part in a clinical trial? Sure, just pay me

Cancer implications as new molecule can kill ‘zombie’ cells

FDA approves first topical gene therapy for dystrophic epidermolysis bullosa wound treatment

Kelonia presents ‘compelling evidence’ for transformative multiple myeloma treatment

Swedish company develops first effective treatment for hypothyroidism

Researchers make cancer weight loss pathway discovery

Subscribe to our newsletter to get the latest biotech news!